![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
The item has been added to your shopping cart.
Home » Serono, Genmab Sign Worldwide Agreement for HuMax-TAC
Serono, Genmab Sign Worldwide Agreement for HuMax-TAC
Serono and Genmab A/S have signed an agreement under which Genmab grants Serono exclusive worldwide rights to develop and commercialize Genmab's HuMax-TAC.
The product is a fully human monoclonal antibody targeting the TAC antigen -- also known as CD25, or the interleukin-2 receptor alpha subunit -- which is overexpressed by activated T-cells. By inhibiting the proliferation of T-cells, HuMax-TAC may have therapeutic potential in the treatment of T-cell mediated diseases, such as autoimmune disorders, inflammatory and hyperproliferative skin disorders, as well as acute transplant rejection. HuMax-TAC is currently in preclinical trials.
Under the agreement, Genmab will receive an upfront payment of $2 million and is entitled to potential milestone payments of up to $38 million and royalties on sales from any eventual commercialization of the product. Serono will be responsible for all future development costs for HuMax-TAC.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct